Meeting
2023 ASCO Genitourinary Cancers Symposium
Radiographic progression-free survival (rPFS) and time to radiographic progression (TTrP) as surrogate endpoints in docetaxel-naïve metastatic castrate resistant prostate cancer (mCRPC): A pooled analysis of COU-AA-302 and ACIS.
Authors
Soumyajit Roy
Rush University Medical Center, Chicago, IL
Soumyajit Roy , Yilun Sun , Daniel Eidelberg Spratt , Scott C. Morgan , Thomas Kim , Julia Malone , Christopher J.D. Wallis , Amar Upadhyaya Kishan , Fred Saad , Shawn Malone
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 136)
DOI
10.1200/JCO.2023.41.6_suppl.136
Abstract #
136
Poster Bd #
D17
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A prospective trial of apalutamide and abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
First Author: Daniel J. George
Poster
2024 ASCO Genitourinary Cancers Symposium
Evaluating early changes in circulating tumor DNA (ctDNA) tumor fraction (TF) as a value add to PSA in predicting early progression in metastatic castrate resistant prostate cancer (mCRPC).
First Author: Christopher Sweeney
Poster
2022 ASCO Genitourinary Cancers Symposium
Statin type and survival of patients with metastatic castrate-resistant prostate cancer receiving abiraterone and enzalutamide: A nationwide retrospective cohort study.
First Author: Harrison Yoon
Poster
2022 ASCO Genitourinary Cancers Symposium
Liquid biopsy AR/enhancer alteration detection before AR-targeted therapy and correlation with survival in metastatic castrate-resistant prostate cancer patients.
First Author: Alexander Shiang